Core technologies
Restoring healthy skin requires more than delivering beneficial ingredients. It also requires conditions that allow them to work at their full potential. Chitogen™ helps support and stabilize the skin's microenvironment, providing a foundation that enhances the performance of other active ingredients.
CORE TECHNOLOGY 01
Conventional chitosan dissolves only under acidic conditions, which has limited its use in skin applications. MEDIFAB introduced carboxymethyl groups into chitosan to enable stable dissolution in neutral water and physiological environments.
CORE TECHNOLOGY 02
Maintains a neutral, liquid state before application. Once absorbed, it reacts with the skin's ionic environment and transforms into a dense gel matrix, helping active ingredients remain localized within the skin for longer periods.
| Material | Key features | Limitations of material use | Chitogen™ differentiators from MEDIFAB proprietary technology |
|---|---|---|---|
| Chitosan | Excellent biocompatibility and antimicrobial properties[6-8] | Soluble only under acidic conditions, limiting injectable use[6-8] | A water-soluble chitosan-based MEDIFAB proprietary ingredient that gels in the body via LTG technology |
| PLLA | Biodegradable polymer that induces collagen production[1-3] | Particle-based formulation requiring reconstitution; tissue reactions reported after treatment[1-3] | A liquid formulation enabling more uniform injection versus PLLA |
| PDLLA | More uniform degradation compared with PLLA[1-3] | Particle-based formulation with potential for early tissue reaction[1-3] | A uniform non-particulate liquid enabling even distribution in tissue versus PDLLA |
| PDRN | Used for tissue recovery and skin improvement[4,5] | Relatively rapid in-body degradation may limit persistence[4,5] | Gels in the body via LTG versus PDRN, creating a stable and sustained environment for active ingredients |
| Exosome | Bioactive vesicles supporting intercellular signaling[5] | Manufacturing standardization, quality consistency, and storage stability are key considerations[5] | A nano-reservoir structure versus exosomes that helps prevent premature degradation and can be combined with bioactive ingredients |
Reference
[1] Journal of Cutaneous and Aesthetic Surgery (JCAS), 2026. [2] Cureus, 2026. [3] StatPearls, 2024. [4] PubMed PMID: 39339047, 2024. [5] PMC11644387, 2024. [6] Biomaterials, 2002. [7] Environmental Chemistry Letters, 2019. [8] Macromolecular Bioscience, 2022.
Patents
2020
Thermosensitive Chitosan Hydrogel Composition and Bioink Composition Comprising the Same
2022
Composition for Manufacturing Thermosensitive Tissue-Repair Biomaterial and Use Thereof
2022 · PCT 2022
Composition for Manufacturing Multi-Crosslinked Thermosensitive Hydrogel and Use Thereof
2024 · PCT 2024
Composition for Manufacturing In-Vivo Ion-Sensitive Tissue-Repair Biomaterial and Use Thereof (KR Registered · JP/US/CN/EU 2026)
2026
Composition for Manufacturing Multi-Crosslinked Thermosensitive Hydrogel and Use Thereof
Publications
2022
Novel Chitosan Dermal Filler with Enhanced Moldability and Elasticity
Macromolecular Bioscience, 2022
Government Projects
2020. 04 - 2021. 03
4th-Generation Filler Technology Based on Thermosensitive Hydrogel (Ministry of Science and ICT)
2020. 04 - 2021. 12
Commercialization of Filler Products Using Thermosensitive Hydrogel Manufacturing Technology (KHIDI)
2020. 07 - 2022. 07
Development of Functional Hydrogel Biomaterials for Tissue Repair (Related Program)
Even in a favorable environment, cells cannot initiate an appropriate recovery response without the biological signals required for repair. Regentrix™ is a xenogeneic dermis-derived decellularized extracellular matrix (dECM) that provides ECM-derived signals damaged tissue can recognize, supporting recovery. Cellular components that could trigger an immune response are removed, and key ECM components are preserved at high purity. In particular, it delivers signals that help type III collagen production, creating an environment in which the skin's innate recovery mechanisms can operate.
CORE TECHNOLOGY 01
Instead of the surfactants used in conventional decellularization, a supercritical CO₂ process is employed to remove immunogenic components while preserving more than 80% of ECM constituents (collagen, elastin, GAG) and growth factors, resulting in high-quality dECM.
CORE TECHNOLOGY 02
Telopeptides, which can induce immune responses, are removed through a proprietary process, creating a dECM platform that can be formulated as either powder or water-soluble form.
| Comparison item | Regentrix™ | Human-derived ECM (hADM) |
|---|---|---|
| Core material | Porcine dermis-derived dECM | Human-derived dermal ECM |
| Manufacturing process | Supercritical CO₂-based decellularization | Varies by manufacturer and process |
| Quality consistency | Standardized raw material and process | May vary with donor characteristics |
| ECM retention | Over 80% retained compared to the original tissue | Retention rate may vary by process |
| Supply stability | Secured through HACCP-certified sourcing | May fluctuate with donation availability |
| Ethical considerations | Commercially farmed raw materials | Consideration of ethical issues arising from the use of human tissue |
Patents
2023 · PCT 2024
Water-Soluble Decellularized Matrix Based on a Supercritical Carbon Dioxide Process (KR Filed · JP/US/CN/EU 2025)
2025 · PCT 2024
Method for Manufacturing a Decellularized Matrix with Enhanced Biocompatibility (KR Registered · JP/US/CN/EU 2026)
Publications
2026
Amine-functionalized chitosan/dECM composite promotes cutaneous regeneration and hair follicle activation.
Adv. Healthcare Mater., e04383
2025
Supercritical fluid-processed hybrid dECM with chitosan hydrogel for improving photoaged dermis.
Adv. Healthcare Mater.
Government Projects
2020. 04 - 2024. 12
Regenerative Medicine Product Commercialization via Tissue-Derived ECM Bioink (KEIT)
2022. 05 - 2024. 04
Dual-Crosslinked Injectable Filler Containing Decellularized Adipose Tissue (TIPA)
Chitogenix™ combines Chitogen™, which creates an optimal regenerative environment, with Regentrix™, which delivers ECM-derived regenerative signals. Instead of simply adding active ingredients or applying external stimulation, Chitogenix™ combines the conditions and the signals together, helping cells support their own recovery. In WST assays using human dermal fibroblasts, it recorded the highest cell viability across every H₂O₂ concentration tested.
I. Excellent recovery efficacy1
Dermal thickness vs. PN in a photoaged skin model
II. Anti-inflammatory effect2
Inflammatory cytokines (TNF-α, IL-6)
III. Antioxidant effect2
Inhibition of reactive oxygen species (ROS)
1) MEDIFAB internal R&D results
2) Kim YJ et al. Advanced Healthcare Materials (2026)
Chitogen™ creates an environment that supports cell regeneration, while Regentrix™ provides ECM-derived signals. Chitogenix™ integrates these two technologies into a single platform, combining a supportive environment with signals that help cells recover.
Patents
2023 · PCT 2024
Composition Comprising a Chitosan Derivative and Decellularized Extracellular Matrix Hydrolysate, and Use Thereof (KR Filed · JP/US/CN/EU 2026)
Publications
2026
Amine-functionalized chitosan/dECM composite promotes cutaneous regeneration and hair follicle activation.
Adv. Healthcare Mater., e04383
Government Projects
2024. 06 - 2028. 12
High-Strength Organic-Inorganic Hybrid Bone Regeneration Material with Osteoimmune Regulation (KEIT)
2025. 07 - 2027. 12
Hybrid Osteoarthritis Treatment with Steroid-Alternative Anti-Inflammatory and Cartilage-Preserving Properties (KEIT)
Korean Korean 
English
Japanese
Chinese
